Glioblastoma diagnostics and prognostic biomarkers: Current status in medicine and exosome derivation

Publication date: Available online 9 March 2019Source: Current Medicine Research and PracticeAuthor(s): Rashmi Rana, Binay Kumari, Jyoti KumariAbstractGlioblastoma multiforme is the most fatal form of brain tumor, distinguished as an aggressive growth and assists annexing by cell relocation and mortification of extracellular matrix with average survival rate of approximately 6-14 months, majority of patients suffer recurrence due to molecular heterogeneity of glioblastoma and deregulation of many signalling pathways involved in proliferation, survival and apoptosis. A number of potential diagnostic, prognostic, and predictive biomarkers have been explored i.e. ATRX, GFAP, Ki67, p53 and IDH markers which helps in diagnosis of glioblastoma patients. The contemporary treatment of glioblastoma involves surgery succeeded by radiotherapy, chemotherapy and adjuvant therapies however current therapies display limited clinical success. Furthermore, in future prospective, exosomes play exponentially multiple roles in the intercellular communication in both normal and disease conditions. Several features of exosomes present them as pioneering indicators to recognize cancer biomarkers for early diagnosis of the diseases and uses as therapeutics.
Source: Current Medicine Research and Practice - Category: General Medicine Source Type: research